Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more
Alaunos Therapeutics Inc (TCRT) - Total Liabilities
Latest total liabilities as of September 2025: $921.00K USD
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has total liabilities worth $921.00K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alaunos Therapeutics Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how Alaunos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alaunos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Alaunos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sarytogan Graphite Ltd
AU:SGA
|
Australia | AU$341.96K |
|
PT Superior Prima Sukses Tbk
JK:BLES
|
Indonesia | Rp969.97 Billion |
|
Sundaram Multi Pap Limited
NSE:SUNDARAM
|
India | ₹319.38 Million |
|
Cemat A/S
CO:CEMAT
|
Denmark | Dkr190.90 Million |
|
Sienna Resources Inc
PINK:SNNAF
|
USA | $160.30K |
|
Bulletin Resources Limited
F:7BR
|
Germany | €525.01K |
|
PT Agung Menjangan Mas Tbk
JK:AMMS
|
Indonesia | Rp2.02 Billion |
|
Mountain Province Diamonds Inc
PINK:MPVDF
|
USA | $651.57 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Alaunos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alaunos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alaunos Therapeutics Inc (2001–2024)
The table below shows the annual total liabilities of Alaunos Therapeutics Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $692.00K | -64.62% |
| 2023-12-31 | $1.96 Million | -92.59% |
| 2022-12-31 | $26.38 Million | -28.33% |
| 2021-12-31 | $36.81 Million | +64.59% |
| 2020-12-31 | $22.36 Million | +58.56% |
| 2019-12-31 | $14.10 Million | +48.67% |
| 2018-12-31 | $9.49 Million | -95.31% |
| 2017-12-31 | $202.41 Million | +10.22% |
| 2016-12-31 | $183.65 Million | +176.77% |
| 2015-12-31 | $66.35 Million | +482.25% |
| 2014-12-31 | $11.40 Million | -49.06% |
| 2013-12-31 | $22.37 Million | -36.01% |
| 2012-12-31 | $34.96 Million | -4.22% |
| 2011-12-31 | $36.50 Million | +17.87% |
| 2010-12-31 | $30.97 Million | +43.15% |
| 2009-12-31 | $21.63 Million | +270.79% |
| 2008-12-31 | $5.83 Million | -8.22% |
| 2007-12-31 | $6.36 Million | +113.37% |
| 2006-12-31 | $2.98 Million | +30.07% |
| 2005-12-31 | $2.29 Million | +10782.70% |
| 2004-12-31 | $21.05K | -18.17% |
| 2003-12-31 | $25.72K | +44.21% |
| 2002-12-31 | $17.84K | +224.27% |
| 2001-12-31 | $5.50K | -- |